The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Efficacy study of artemether-lumefantrine for the treatment of malaria in Solomon Islands.
Scientific title
Efficacy study of artemether-lumefantrine for the treatment of Plasmodium falciparum (P. falciparum or Pf) and Plasmodium vivax (P. vivax or Pv) in Solomon Islands.
Secondary ID [1] 286514 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Malaria infection 294729 0
Condition category
Condition code
Infection 295018 295018 0 0
Other infectious diseases
Public Health 295280 295280 0 0

Study type
Description of intervention(s) / exposure
Patients with a microscopically confirmed P. falciparum or P. vivax infection on day 0 will be administered a fixed dose combination of artemether (20 mg) and lumefantrine (120 mg) (CoartemTM, Novartis) as a six-dose regimen twice a day for three days according to body weight under direct supervision by the study team. The mode of administration is oral dosing as follows: 5 to <15 kg bodyweight: 1 tablet per dose; 15 to <25 kg: 2 tablets per dose; 25 to <35 kg: 3 tablets per dose; =35 kg: 4 tablets per dose. In addition, the Pv group will also receive oral primaquine once daily for 14 days (0.25 mg base/kg/day), starting on Day 28 after completion of the 28-day follow-up. The study patients will be observed for 30 min after drug administration for adverse reactions or vomiting. Any patient who vomited during this observation period will be re-treated with the same dose of AL and observed for an additional 30 min. Patients are requested to return to the clinic on days 1, 2, 3, 7, 14, 21 and 28 for clinical and parasitological assessment as per protocol follow up schedule, or whenever they did not feel well.
Intervention code [1] 291605 0
Treatment: Drugs
Intervention code [2] 292289 0
Diagnosis / Prognosis
Comparator / control treatment
No control group
Control group

Primary outcome [1] 294773 0
Primary Outcome 1: To assess the therapeutic efficacy of artemether-lumefantrine (AL, Coartem Trademark) combination therapy for the treatment of uncomplicated Plasmodium falciparum and P. vivax infections in an area of Solomon Islands. The efficacy of AL in the two groups are compared by the number of patients cured of their infection over a 28-day follow-up period. Recrudescence of infection will be determined by Polymerase Chain Reaction (PCR) analysis. Early treatment failure (ETF), late parasitological failure (LPF), late clinical failure (LCF) and late parasitological failure (LPF) as defined in WHO (2003: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization. 68 pp). Note: Primaquine was administered after Day 28, hence the effect of artemether-lumefantrine combination therapy was solely evaluated in this group.
Timepoint [1] 294773 0
Absence of parasitaemia on day 28 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure (ETF) or Late Clinical Failure (LCF) or Late Parasitological Failure (LTF).
Secondary outcome [1] 314017 0
Timepoint [1] 314017 0
Absence of side effects up to 28 days post-treatment
All patients will be asked about old symptoms and new symptoms emerging since previous visit during the follow-up. Known possible side effects include stomach cramps, nausea, vomiting and diarrhoea. Where clinically indicated patients will be evaluate and treated appropriately. All adverse events will be recorded on the case reporting form. For a patient who vomits twice, the patient will be withdrawn from the study and he/she will given rescue treatment.

Key inclusion criteria
(i) Sex: male or female
(ii) Age: between 1 year and 65 years old
(iii) Falciparum or vivax infection with parasitemia between 500 and 100,000 parasites/ul of blood
(iv) History of fever during 48 hours prior to time of recruitment
(v) Ability to swallow oral medication
(vi) Is willing to give small amounts of blood via finger prick
(vii) Written informed consent from the patient or parent/guardian (in the case of young children), assent from child (ages 8-17 years inclusive).
(viii) Written informed consent and agreed to treatment follow-up for a total of 28 days
(ix) Willingness on the part of the patient to return to the clinic for scheduled check-ups during the 28-day follow-up period
Minimum age
1 Years
Maximum age
65 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
(i) Severe/cerebral malaria or history of another serious medical disease
(ii) Prior treatment with an artemisinin or another antimalarial drug within the previous 7 days
(iii) Pregnancy and lactating
(iv) Inability to communicate well with the investigator (poor mental development or evidence of psychiatric disorder)
(v) Are likely to be absent from the household during the study period.
(vi) Chronic infectious diseases other than malaria (e.g. tuberculosis)
(vii) Known allergy and/or intolerance to drug(s) being tested

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation of drugs was not concealed. Patients were sequentially enrolled and given treatment: CoArtem (a fixed dose combination of artemether (20 mg) and lumefantrine (120 mg) as a six-dose regimen twice a day for three days. For the P. vivax group, patients were administered primaquine daily for 14 days at the presecribed dose according to body weight after Day 28.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Both Pf and Pv group of patients received 3-day artemether-lumefantrine. But the Pv group received an additional oral primaquine once daily for 14 days (0.25 mg base/kg/day), starting on Day28 after completion of the 28-day follow-up.
Phase 4
Type of endpoint(s)
Statistical methods / analysis
Assuming an expected treatment failure rate of 5% with artemether-lumefantrine, a power of 80%, and a 5% level of significance, 59 subjects will need to be enrolled in each of the Pf or Pv group. A 15% drop-out (or loss to follow-up) can be expected during a 28-day study, so a total of 70 patients should be enrolled in each of the Pf or Pv group

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 6804 0
Solomon Islands
State/province [1] 6804 0
Malaita Province

Funding & Sponsors
Funding source category [1] 291080 0
Name [1] 291080 0
World Health Organization
Address [1] 291080 0
Regional Office for the Western Pacific
P.O. Box 2932
1000 Manila
Country [1] 291080 0
Primary sponsor type
Government body
Ministry of Health
Vector Borne Disease Control Program Tongs Building, Hibiscus Avenue,, Honiara
Solomon Islands
Secondary sponsor category [1] 289757 0
Name [1] 289757 0
Address [1] 289757 0
Country [1] 289757 0
Other collaborator category [1] 278431 0
Government body
Name [1] 278431 0
Australian Malaria Institute
Address [1] 278431 0
Weary Dunlop Drive, Gallipoli Barracks, Enoggera, Qld 4208.
Country [1] 278431 0

Ethics approval
Ethics application status
Ethics committee name [1] 292663 0
National Health Research Ethics Committee, Solomon Islands
Ethics committee address [1] 292663 0
Ministry of Health, P.O. Box 349, Honiara
Ethics committee country [1] 292663 0
Solomon Islands
Date submitted for ethics approval [1] 292663 0
Approval date [1] 292663 0
Ethics approval number [1] 292663 0

Brief summary
To assess the efficacy of artemether- lumefantrine for the treatment of uncomplicated P. falciparum and P. vivax infections in Solomon Islands using the WHO 28-day protocol.

The null hypothesis is that patients who take artemether-lumefantrine (CoArtem) for the treatment of uncomplicated P. falciparum and P. vivax infections have similar clinical and parasitological outcomes.
Trial website
Trial related presentations / publications
Study results were presented and reported at a World Health Organization Western Pacific Regional therapeutic efficacy meeting "Pacific Malaria Drug Resistance Monitoring Network Meeting Report, Manila, 8-9 August 2011." Country update on national malaria drug efficacy monitoring, Solomon Islands (2007-2011), presentor: Dr Lyndes Wini, Medical Officer, Vector-Borne Diseases Control Programme, Ministry of Health & Medical Services, Solomon Islands.
Public notes

Principal investigator
Name 56442 0
Dr Lyndes Wini
Address 56442 0
Locked Bag, National Vector Borne Diseases Control Program, Ministry of Health and Medical Services, Honiara, Solomon Islands
Country 56442 0
Solomon Islands
Phone 56442 0
Fax 56442 0
Email 56442 0
Contact person for public queries
Name 56443 0
Dr Jeffrey Hii
Address 56443 0
Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvidhi Rd, Bangkok 10400
Country 56443 0
Phone 56443 0
+66 (0)9 03025573
Fax 56443 0
+66 (0) 2354 5629
Email 56443 0
Contact person for scientific queries
Name 56444 0
Dr Jeffrey Hii
Address 56444 0
Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvidhi Rd, Bangkok 10400
Country 56444 0
Phone 56444 0
+66 (0)9 03025573
Fax 56444 0
+66 (0) 2354 5629
Email 56444 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary